Le notizie dalla Borsa Italiana del adaptive-biotechnologies-highlights-new-data-at-asco-2023-and-eha-2023-underscoring-the-clonoseq-assay-s-impact-as-a-standard-for-minimal-residual-disease-assessment-in-patients-with-hematologic-cancer-1419304


Condividi